The MARGOT/TBCRC052 trial failed to show a significant improvement in pathologic complete response (pCR) rates with margetuximab compared with trastuzumab in patients with early-stage HER2-positive ...

Sorry, Hollywood. Indie studios have officially taken over the poster game. Of the 25 films listed below, I can count the number of legacy studios on one hand (even ...

After hours: January 29 at 4:08:12 PM EST Loading Chart for MGNX ...

Treatment for HER2-positive breast cancer depends on tumor size and spread but may involve a combination of chemotherapy, targeted therapy, monoclonal antibody therapy, and kinase inhibitors. HER2 ...